COVID-19 IMI2–Call 21
CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats.
Search
GlyT1 Phase II results
Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Empowering all employees
Boehringer Ingelheim has been awarded as a Global Top Employer for the second year in succession
World Water Day: Good Health Hinges on Good Water
Clean, safe and accessible water is the most basic prerequisite for life and health
The big, the bold, and the few
In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
Lead with Pride – for the Benefit of All.
How Inclusive Leadership advocates for Acceptance and creating a Sense of Belonging
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
1990-2022: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2022, with milestones
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Bringing Precision to Psychiatry
Dr. Hugh Marston and Dr. Vikas Mohan Sharma discuss how precision psychiatry can enable people living with mental health conditions to thrive.